Literature DB >> 14618242

The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma.

S Jindrichova1, R Kodet, L Krskova, P Vlcek, B Bendlova.   

Abstract

Medullary thyroid carcinoma (MTC) occurs as a sporadic form or, less frequently, as an autosomal dominant inherited familial disorder. Germline mutations in the RET proto-oncogene in exons 10, 11, 13, 14, 15, and 16 are found in most of the familial cases (nearly 95%). Somatic mutations in sporadic MTC are detected in 23-69% of patients. The most frequent somatic mutation is located in exon 16 at codon 918, and only a small percentage of mutations are found in exons 10, 11, 13, and 15. We have searched for somatic mutations in Czech MTC patients using direct sequencing. We report here two new somatic missense mutations in exon 16 of the RET proto-oncogene associated with the sporadic MTC detected in two Czech men. A homozygous mutation at codon 922 TCC(Ser)-->CCC(Pro) as a result of loss of heterozygosity was revealed in the first patient. In the second one a heterozygous mutation at codon 930 ACG(Thr)-->ATG(Met) was found.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14618242     DOI: 10.1007/s00109-003-0501-4

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  26 in total

1.  Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918.

Authors:  Fred H Menko; Rob B van der Luijt; Irene A J de Valk; Arno W F T Toorians; Jan M Sepers; Paul J van Diest; Cornelis J M Lips
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

2.  A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma.

Authors:  M Alemi; S D Lucas; J F Sällström; U Bergholm; G Akerström; E Wilander
Journal:  Oncogene       Date:  1997-05-01       Impact factor: 9.867

3.  Catalytic specificity of protein-tyrosine kinases is critical for selective signalling.

Authors:  Z Songyang; K L Carraway; M J Eck; S C Harrison; R A Feldman; M Mohammadi; J Schlessinger; S R Hubbard; D P Smith; C Eng
Journal:  Nature       Date:  1995-02-09       Impact factor: 49.962

4.  A novel deletion in the RET proto-oncogene found in sporadic medullary thyroid carcinoma.

Authors:  M Alemi; S D Lucas; J F Sällström; G Akerström; E Wilander
Journal:  Anticancer Res       Date:  1996 Sep-Oct       Impact factor: 2.480

5.  Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium.

Authors:  L M Mulligan; D J Marsh; B G Robinson; I Schuffenecker; J Zedenius; C J Lips; R F Gagel; S I Takai; W W Noll; M Fink
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

6.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

7.  Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease.

Authors:  T Attié; A Pelet; P Edery; C Eng; L M Mulligan; J Amiel; L Boutrand; C Beldjord; C Nihoul-Fékété; A Munnich
Journal:  Hum Mol Genet       Date:  1995-08       Impact factor: 6.150

8.  Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma.

Authors:  C Eng; L M Mulligan; D P Smith; C S Healey; A Frilling; F Raue; H P Neumann; R Pfragner; A Behmel; M J Lorenzo
Journal:  Genes Chromosomes Cancer       Date:  1995-03       Impact factor: 5.006

9.  Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.

Authors:  C Romei; R Elisei; A Pinchera; I Ceccherini; E Molinaro; F Mancusi; E Martino; G Romeo; F Pacini
Journal:  J Clin Endocrinol Metab       Date:  1996-04       Impact factor: 5.958

10.  Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.

Authors:  S Uchino; S Noguchi; H Yamashita; M Sato; M Adachi; H Yamashita; S Watanabe; A Ohshima; S Mitsuyama; T Iwashita; M Takahashi
Journal:  Jpn J Cancer Res       Date:  1999-11
View more
  3 in total

1.  Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display.

Authors:  Thomas J Musholt; Julia Hanack; Christoph Brehm; Reinhard von Wasielewski; Petra B Musholt
Journal:  World J Surg       Date:  2005-04       Impact factor: 3.352

Review 2.  RET and neuroendocrine tumors.

Authors:  Yoshiki Murakumo; Mayumi Jijiwa; Naoya Asai; Masatoshi Ichihara; Masahide Takahashi
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

3.  Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.

Authors:  M M Moura; B M Cavaco; A E Pinto; R Domingues; J R Santos; M O Cid; M J Bugalho; V Leite
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.